Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance
- 1st Edition - June 1, 2027
- Latest edition
- Editors: Mariza Vorster, Mike Sathekge
- Language: English
Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance serves as a vital resource in the evolving field of nuclear medicine, highli… Read more
Description
Description
Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance serves as a vital resource in the evolving field of nuclear medicine, highlighting the transformative potential of theranostic strategies that combine targeted diagnostic imaging with precision radionuclide therapies. The content explores the integration of theranostic techniques into treatment paradigms for cancer, emphasizing the unique advantages of nuclear medicine therapies, including reduced side effects, improved quality of life, outpatient accessibility, and cost-effectiveness. For an academic audience, this volume equips clinicians and researchers with insights to enhance patient outcomes by effectively integrating these innovative therapies into clinical practice. The book addresses the pressing challenge of treatment resistance in oncology, providing healthcare professionals with a comprehensive understanding of the latest advancements and their applications. By embracing these advancements, healthcare professionals can contribute to personalized medicine and better address treatment resistance in their patients.
Key features
Key features
- Examines the biological mechanisms underlying cancer treatment resistance and the role of theranostic strategies in overcoming these challenges
- Explores radiopharmaceutical design, molecular imaging, dosimetry, and personalised treatment planning to optimize radionuclide therapy outcomes
- Reviews combination and tandem treatment approaches across prostate cancer, breast cancer, and neuroendocrine tumours, highlighting current advances in precision nuclear medicine
Readership
Readership
Scientists and scholars in the fields of oncology, nuclear medicine, radiopharmaceuticals, and related disciplines
Table of contents
Table of contents
1. Introduction
2. Mechanisms of Treatment Resistance
3. Principles of Theranostics in Nuclear Medicine
4. Theranostic Agents, Development and Novel Delivery Approaches
5. Applications in Oncology
6. Emerging Applications Beyond Oncology
7. Combination Strategies, Tandem Approaches and Place in Treatment Landscape
8. Dosimetry and Personalized Treatment Planning
9. Challenges and Limitations in Theranostic Applications
10. Conclusions and Future Directions
2. Mechanisms of Treatment Resistance
3. Principles of Theranostics in Nuclear Medicine
4. Theranostic Agents, Development and Novel Delivery Approaches
5. Applications in Oncology
6. Emerging Applications Beyond Oncology
7. Combination Strategies, Tandem Approaches and Place in Treatment Landscape
8. Dosimetry and Personalized Treatment Planning
9. Challenges and Limitations in Theranostic Applications
10. Conclusions and Future Directions
Product details
Product details
- Edition: 1
- Latest edition
- Published: June 1, 2027
- Language: English
About the editors
About the editors
Mariza Vorster
Editor
Prof Mariza Vorster is the Academic and Clinical Head of the Department of Nuclear Medicine at the University of KwaZulu-Natal, which spans three hospital sites in Durban. She began Ac-225-PSMA and DOTATATE therapy in KwaZulu-Natal in January 2023 and received the ICPO's Maurits W Geerlings award that year. In 2025 her department was accredited as an ICPO Theranostic Centre of Excellence. She is Immediate Past President of the College of Nuclear Physicians (2020 to 2026) and serves as an examiner, convenor and senator for the Colleges of Medicine of South Africa. She chairs the International Scientific Steering Committee for NuMeRI, serves as Secretary of the International Society of Radiolabelled Blood Elements (ISORBE), is an Ambassador for the Oncidium Foundation, and is a member of the UroTerag LATAM Global Expert Panel. Prof Vorster is an IAEA expert and collaborator and has authored and co-authored over 150 peer-reviewed publications. Her research interests include novel Ga-68 based tracer applications and theranostics aimed at solving important clinical problems.
Affiliations and expertise
Associate Professor and Head of Department, Department of Nuclear Medicine, University of KwaZulu-Natal, Durban, South AfricaMike Sathekge
Editor
Professor Mike Sathekge is President and CEO of the Nuclear Medicine Research Infrastructure (NuMeRI) and Head of Nuclear Medicine at Steve Biko Academic Hospital and the University of Pretoria. He is internationally recognised for his leadership in radiotheranostics and targeted alpha therapy, having served as principal investigator on multiple early-phase studies. Mike Sathekge plays a key role in translational research at the interface of academia, healthcare systems, and industry, supporting the development, validation, and clinical adoption of novel radiopharmaceuticals. He has published extensively and is Editor-in-Chief of Seminars in Nuclear Medicine and providing strategic oversight of emerging scientific and clinical trends. He leads the IAEA Anchor Centre for Rays of Hope for cancer care in South Africa and is Co-Chair of the National Cancer Research Innovation Strategy (NCRIS). He currently serves as Chair of the Africa Health Research Institute (AHRI). Professor Sathekge is the recipient of numerous national and international honours.
Affiliations and expertise
Professor and Head, Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa